Division Highlights - Hematology & Oncology
The Division of Hematology and Oncology provides state-of-the-art integrated therapies, including stem cell transplant, aimed at curing malignancies and treating hematological disorders in children.
Research interests include ways to recognize and destroy cancer cells using immunologic and molecular biologic pathways, cancer survivorship, and palliative care.
- Carol Diamond, MD, was one of the first recipients of UW Health’s Clinical Practice Excellence Award.
- Kenneth DeSantes, MD, led a large collaborative team at American Family Children’s Hospital to initiate a program that is routinely administering I-131 MIBG treatment for high-risk neuroblastoma, making the AFCH one of seven centers nationally that are providing this innovative treatment.
- Paul Sondel, MD, PhD, was senior author of a national trial reported in The New England Journal of Medicine. The trial tested an experimental immunotherapy treatment, based in part on his laboratory’s work, for children with high-risk neuroblastoma. It showed a 20% improvement in cure rates for children who received this immunotherapy.
Professor and Division Chief
Delgado D, Webster DE, DeSantes KB, Durkin ET, Shaaban AF. KIR receptor-ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells. Pediatr Blood Cancer. 2010 Dec 15;55(7):1300-5.
Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fc Œ≥ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1;70(23):9554-61.
Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20;28(33):4969-75.
Manousakis G, Hsu D, Diamond CA, Rowley H. Teaching NeuroImages: methotrexate leukoencephalopathy mimicking a transient ischemic attack. Neurology. 2010 Aug 17;75(7):e34.
Allen CE, Flores R, Rauch R, Dauser R, Murray JC, Puccetti D, Hsu DA, Sondel P, Hetherington M, Goldman S, McClain KL. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar;54(3):416-23.
Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011 Feb;132(2):226-39.
Galili U, Albertini MR, Sondel PM, Wigglesworth K, Sullivan M, Whalen G. In situ conversion of melanoma lesions into autologous vaccine by intratumoral injections of a-gal glycolipids. Cancers. 2010;2:773-793.
Johnson EE, Buhtoiarov IN, Baldeshwiler MJ, Felder MA, Van Rooijen N, Sondel PM, Rakhmilevich AL. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother. 2011 Jan;34(1):76-84.
Mackall CL, Sondel PM. Tumor Immunology and Pediatric Cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th Edition. Philadelphia: Lippincott Raven; 2010, 97-122.
Yang RK, Sondel PM. Anti-GD2 strategy in the treatment of neuroblastoma. Drugs Future. 2010;35(8):665.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen H, Smith M, Anderson B, Villablanca J, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Chimeric anti-GD2 antibody with GM-CSF, IL2 and 13-cis retinoic acid for high-risk neuroblastoma: A Children’s Oncology Group (COG) phase 3 study. N Engl J Med. 2010;335:1324-1334.
|Principal Investigator||Funding Agency||Title|
|DeSantes, Kenneth||Midwest Athletes Against Childhood Cancer||Support for Research Data Management|
|DeSantes, Kenneth||Midwest Athletes Against Childhood Cancer||Reduced Intensity Haploidentical Transplantation with NK Cell Infusions for Pediatric Acute Leukemia and High Risk Solid Tumors|
|DeSantes, Kenneth||National Childhood Cancer Foundation||Per Case & Specimen Reimbursement|
|DeSantes, Kenneth||National Childhood Cancer Foundation||A Phase III Study of Chimeric Antibody 14.18 in High-Risk Neuroblastoma|
|DeSantes, Kenneth||National Childhood Cancer Foundation||Children's Oncology Group Chair|
|DeSantes, Kenneth||Pfizer, Inc.||A Prospective, Open-Label, Non-Randomized, Multi-Center Study to Investigate the Safety and Tolerability of Voriconazole As Primary Therapy for Treatment of Invasive Aspergillosis and Molds such as Scedosporium or Fusarium Species in Pediatric Patients|
|DeSantes, Kenneth||Solving Kids Cancer||Reduced Intensity Haploidentical Transplantation with NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors|
|Diamond, Carol||Medical College of Wisconsin||Molecular and Clinical Biology of von Willebrand Disease|
|Diamond, Carol||American Red Cross||American Red Cross Hematology Support|
|Dovat, Sonny||DHHS, PHS, National Institutes of Health||The Role of Zinc Finger Genes in Leukemogenesis|
|Dovat, Sonny||Midwest Athletes Against Childhood Cancer||The Role of Ikaros in Malignant Transformation|
|Dovat, Sonny||St. Baldrick’s Foundation||The Role of Ikaros in Myeloid Differentiation|
|Puccetti, Diane||Osi Pharmaceuticals, Inc.||A Randomized, Phase 2 Study of Single-Agent Erlontinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||Antitumor Mechanisms of Anti-CD40/CpG-Activated Macrophages|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||Combination of Resveratrol and Immunotherapy|
|Sondel, Paul||Midwest Athletes Against Childhood Cancer||Development of Intratumoral and Systemic Neuroblastoma Therapy Using Hu14.18-IL2 Plus Resveratrol (RV)|
|Sondel, Paul||Midwest Athletes Against Childhood Cancer||KIR-Incompatible Stem Cell Transplantation for Pediatric Osteosarcoma and Other Pediatric Solid Tumors: A Preclinical Model|
|Sondel, Paul||National Childhood Cancer Foundation||COG Immunotherapy|
|Sondel, Paul||St. Baldrick’s Foundation||COG Neuroblastoma Laboratory|
|Sondel, Paul||Super Jake Foundation||Multivalent Decoration of Neuroblastoma Cells to Mediate Tumor Destruction|
|Sondel, Paul||DOD, Army||Ovarian Cancer Immunotherapy Using Redirected Endogenous Anti-Gal Antibody|
|Sondel, Paul||St. Jude Medical||A Phase I Trial of the Humanized Anti-GD2 Antibody (HU14.18K322A) in Children and Adolescents with Neuroblastoma or Melanoma|
|Sondel, Paul||DHHS, PHS, National Institutes of Health||Clinical Development of HU14.18-IL2 Targeted Therapy|
|Sondel, Paul||Hyundai Hope on Wheels Foundation||Genotyping of KIR,KIR-L and FcR Genes to Improve Outcome for Immunotherapy of Neuroblastoma|
|Sondel, Paul||National Cancer Institute||NCI-Clinical Immunotherapy Trials Consortium|